2178709
Last Update Posted: 2022-04-19
Recruiting has ended
All Genders accepted | 18 Years + |
48 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Phase II Study of Neoadjuvant FOLFIRINOX
The primary objective of this study is to evaluate the rate of pathologic complete response to neoadjuvant FOLFIRINOX in patients with resectable pancreatic cancer using a tissue collection component.
Eligibility
Relevant conditions:
Resectable Pancreatic Ductal Adenocarcinoma
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
No valid contacts available
Data sourced from ClinicalTrials.gov